Science Signaling Podcast: 25 March 2014

See allHide authors and affiliations

Sci. Signal.  25 Mar 2014:
Vol. 7, Issue 318, pp. pc9
DOI: 10.1126/scisignal.2005207

You are currently viewing the abstract.

View Full Text


This Podcast features an interview with Maurizio Scaltriti, author of a Research Article that appears in the 25 March 2014 issue of Science Signaling, about a combination therapy that might be effective against triple-negative breast cancer (TNBC). TNBC is often aggressive and is defined by the absence of overexpression or amplification of the genes encoding the estrogen receptor, the progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although drugs that inhibit signaling through these receptors are effective against other subtypes of breast cancer, these therapies are not effective against TNBC. However, TNBCs often have elevated signaling through the PI3 kinase–Akt pathway and through the epidermal growth factor receptor (EGFR). Tao et al. report that a combinatorial treatment that simultaneously targets the PI3 kinase–Akt pathway and signaling through the related EGFR and HER3 receptors reduced growth of TNBC xenografts in mice.

View Full Text